Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Multiple Myeloma (MM) is a rare (1% of all cancers), incurable form of blood cancer. Conventional oncology has gotten pretty good at putting newly diagnosed MMers into remission. For example, more than 90% of MMers achieve some form of remission when given the chemotherapy triplet RVd (revlimid, velcade, dexamethasone) as an induction therapy. Conventional, FDA approved multiple myeloma therapy however, will never cure multiple myeloma. MM patients must look outside the FDA box and consider multiple myeloma therapies that are evidence-based but non-convention. Consider MGN-3 and curcumin.
The good news is that MM patients achieve remission from their MM. The bad news is that they reach remission only to relapse months or years later. While the list of newly FDA approved MM therapies is long and growing, MM patients eventually achieve multi-drug resistence (MDR), and run out of therapy options.
According to the studies below, MGN-3 kills MM. Curcumin kills MM. Curcumin and MGN-3 synergize to enhance their MM killing properties.
Because low-dose maintenance revlimid has become a standard-of-care therapy for many MMers once they have completed induction therapy, it makes sense to me to add MGN-3 and curcumin therapy to this standard-of-care MM therapy in order to enhance the efficacy of revlimid therapy.
“The immune modulatory effects by both MGN-3 and curcumin have been well documented. Earlier studies have shown that both agents are potent biological response modifiers that have the ability to boost different arms of the immune cells, such as NK cells, T cells, B cells, macro- phages, dendritic cells and Treg cells [11-14, 38-41]…
The present study was carried out to investigate the synergistic apoptotic potential of arabinoxylan rice bran (MGN- 3/Biobran) and curcumin (turmeric) on human multiple myeloma (MM) cell line U266 , in vitro. U266 cells were cultured with MGN-3 (50 or 100μg/ml) and curcumin (2.5-10μM) for 3 days.
The effects of MGN-3 and curcumin on the growth and survival of the U266 cells were determined by trypan blue, MTT assay, flow cytometry analysis of cancer cell cycle, and apoptosis. Expression of proapoptotic Bax, and antiapoptotic Bcl2 was determined by Western blot analysis.
Treatment with MGN-3 alone or curcumin alone caused a dose-dependent inhibition in the proliferation of U266 cells.However, a synergistic effect was noticed post-treatment with both agents that maximized at 100μg/ml MGN-3 plus 10μM curcumin.
This synergy was characterized by an 87% decrease in cell number and a 2.6 fold increase in the percentage of apoptotic U266 myeloma cells. Cell cycle analysis showed a 53% decrease in the percentage of cells in the G0-G1 phase treated with MGN-3 and curcumin (from 36% to 17%).
Analysis of the expression of the pro and antiapoptotic molecules Bax and Bcl-2 revealed synergistic effects of these agents, as the expression of Bcl-2 was decreased and Bax was increased. This resulted in a cellular microenvironment favorable for apoptosis.
We conclude that MGN-3 and curcumin synergize in the induction of U266 cell apoptosis. This data may establish the foundation for in vivo studies that could have therapeutic implications.
These characteristics, in addition to their ability to synergize in inducing apoptosis of cancer cells may add an additional weapon for fighting cancer. This may suggest a rationale for considering the combination of MGN-3 and curcumin in future studies for the treatment of multiple myeloma in clinical trials…
“However, when bortezomib was combined with curcumin, the effects on cellular proliferation and apoptosiswere significantly enhanced, indicating the syn- ergistic effects of curcumin and bortezomib…
In conclusion, our results showed that, curcumin treatment alone significantly inhibited the proliferation and enhanced the apoptosis of MM1.R cells, in a dose-dependent manner. Themonotherapy of bortezomib did not significantlyalter the cell proliferation and apoptotic pro- cess. When the cells were treated with the combination of curcumin and bortezomib, fur- ther suppressed proliferation and enhanced apoptosis would be observed in these MM1.R cells.
In addition, the combination treatment could significantly increase the activation ofcaspase-3 and -9, and decrease the expres-sion levels of NF-κB and HSP-90, in MM1.R cells. Our findings suggest that, curcumin could enhance the sensitivity of MM1.R cells to bort- ezomib, and they could exert synergistic effects on MM1.R cells, inhibiting cell proliferation and enhancing cellular apoptosis, via the regulation of the expression of NF-κB and HSP-90. These findings provide evidence for application of the combination of curcumin and bortezomib in the treatment of MM…”